Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - Αντινεοπλασματικοί παράγοντες - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - Καρκίνωμα, μη μικροκυτταρικός πνεύμονας - Αντινεοπλασματικοί παράγοντες - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

tremelimumab - c/s.sol.in (ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 20mg/ml - tremelimumab 20mg - tremelimumab